Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Pharvaris (PHVS) reported that its deucrictibant tablets reduced HAE attack rates by 83% in a Phase 3 trial. The study met primary and secondary endpoints. PHVS plans a 2027 FDA submission. Results showed sustained attack-rate reductions and no serious adverse events.
How this was made
The 30-second read
Why it matters
The data positions the company for an NDA filing in 2027, potentially unlocking value if approved.
Market read
Positive Phase 3 results are a catalyst for PHVS and may influence the HAE therapeutic space.
What to watch
Regulatory timeline and competitive landscape of injectable HAE treatments.
Background
Pharvaris N.V. is developing an oral bradykinin B2 receptor antagonist for hereditary angioedema.
Ticker impact
Phase 3 CHAPTER-3 trial showed an 83% reduction in HAE attack rates versus placebo, a new primary disclosure.
Potential upside as investors price in approval prospects.
First report of statistically significant Phase 3 results for a microcap biotech; such data historically moves stock sharply.
Market effects
May boost sentiment for HAE therapeutics and oral peptide drugs.
Limited to US biotech sector.
Relevant to global rare‑disease investors.
Counterpoint
Small trial size and limited subgroup data could temper enthusiasm.
Key entities
- companyPharvaris N.V.
Biotech firm developing oral HAE therapy.
